OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Chang on Questions Regarding Molecular Testing in Prostate Cancer

April 23rd 2020

Sam S. Chang, MD, MBA, discusses remaining questions regarding molecular testing in prostate cancer.

Dr. Grivas on the Future of Molecular Subtyping in Urothelial Cancer

April 23rd 2020

Petros Grivas, MD, PhD, discusses the future of molecular subtyping in urothelial cancer.

Dr. Oh on the Importance of Identifying DNA Damage Repair Mutations in Prostate Cancer

April 23rd 2020

William K. Oh, MD, discusses the importance of identifying DNA damage repair mutations in prostate cancer.

Dr. Shah on the Role of Venetoclax in Multiple Myeloma

April 23rd 2020

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the role of venetoclax (Venclexta) in multiple myeloma.

Dr. Bannerji on Ongoing Research With REGN1979 in Non-Hodgkin Lymphoma

April 23rd 2020

Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses ongoing research with the bispecific antibody REGN1979 in non-Hodgkin lymphoma (NHL).

Dr. Graff on the FDA Approval of Sacituzumab Govitecan in TNBC

April 22nd 2020

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses the FDA approval of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC).

Dr. Pettaway on the Prevalence of Germline Mutations in Diverse Populations With Prostate Cancer

April 22nd 2020

Curtis A. Pettaway, MD, professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the prevalence of germline mutations in diverse populations with prostate cancer.

Dr. Polascik on Harmonizing Genetic Testing Guidelines in Prostate Cancer

April 22nd 2020

Thomas J. Polascik, MD, a urologic oncologist at Duke University, discusses efforts that are being made to harmonize genetic testing guidelines in prostate cancer.

Dr. Murthy on the Clinical Implications of Tucatinib Approval in HER2+ Breast Cancer

April 22nd 2020

Rashmi Murthy, MD, MBE, discusses the data that led to the approval of the tucatinib triplet, the clinical implications of the approval on practice, and the next steps for research with the agent.

Dr. Friedman on the Future of Selinexor in Multiple Myeloma

April 22nd 2020

Robb S. Friedman, MD, discusses the future of selinexor in multiple myeloma.

Dr. Kaseb on Safety Profile of Atezolizumab Plus Bevacizumab in HCC

April 22nd 2020

Ahmed O. Kaseb, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

Dr. O'Malley on Antitumor Activity With Veliparib Combo in Serous Ovarian Cancer

April 22nd 2020

David O'Malley, MD, discusses antitumor activity with veliparib in combination with chemotherapy in patients with high grade serous ovarian cancer.

Dr. Rossetti on the Utility of JAK Inhibitors in MPNs

April 22nd 2020

James M. Rossetti, DO, discusses the utility of JAK inhibitors in myeloproliferative neoplasms.

Dr. Michaelis on Potential Combination Strategies With Ruxolitinib in Myelofibrosis

April 22nd 2020

Laura C. Michaelis, MD, discusses potential combination strategies with ruxolitinib in myelofibrosis.

Dr. Yee on Treatment Considerations in Relapsed/Refractory Multiple Myeloma

April 22nd 2020

Andrew Yee, MD, discusses treatment considerations in relapsed/refractory multiple myeloma.

Dr. Brody on the Role of Immunotherapy in Indolent Lymphomas

April 22nd 2020

Joshua Brody, MD, discusses the role of immunotherapy in indolent lymphomas.

Dr. Janjigian on Extensive Intraoperative Peritoneal Lavage in Gastric Cancer

April 21st 2020

Yelena Y. Janjigian, MD, discusses data examining surgery plus extensive intraoperative peritoneal lavage versus surgery alone in patients with gastric cancer.

Dr. Choueiri on the COVID-19 and Cancer Consortium

April 21st 2020

Toni K. Choueiri, MD, discusses the COVID-19 and Cancer Consortium, a multicenter effort to obtain evidence-based information on patients with cancer who have tested positive for the virus.

Dr. Mesa on the Utility of Ruxolitinib Versus Fedratinib in Myelofibrosis

April 21st 2020

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis and baseline thrombocytopenia.

Dr. Davies on Research Efforts in Lenalidomide-Refractory Myeloma

April 21st 2020

Faith E. Davies, MD, discusses the research being done in patients with multiple myeloma who are refractory to lenalidomide.